Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes Study Evaluating the Zero-P PEEK

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic cervical disc disease (SCDD) in only one vertebral level between C3-C7 requiring:~   1. Neck or arm (radicular) pain and/or~  2. Functional/neurological deficit confirmed by imaging (CT, MRI, X-Ray) of at least one of the following:~   i. herniated nucleus pulposus~   ii. spondylosis (defined by presence of osteophytes)~   iii. loss of disc height~2. NDI score greater than or equal to 15/50 (30%) (considered moderate disability);~3. Skeletally mature adult between the ages of 18-70 years at the time of surgery;~4. Has completed at least six (6) weeks of conservative therapy;~5. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures;~6. Personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the study.~Exclusion Criteria:~1. More than one vertebral level to be fused;~2. Posterior instrumentation necessary at same level;~3. Has had previous surgery at the index level;~4. Has a fused level adjacent to the index level;~5. Active systemic or local infection;~6. Known or documented history of communicable disease, including AIDS or HIV;~7. Active hepatitis (receiving medical treatment within two years);~8. Active rheumatoid arthritis, non-controlled diabetes mellitus, or any other medical condition(s) that would represent a significant increase in surgical risk or interfere with normal healing;~9. Immunologically suppressed, or has received systemic steroids, excluding nasal steroids, at any dose daily for \> 1 month within last 12 months;~10. Known history of Paget's disease, osteomalacia, or any other metabolic bone disease;~11. Osteopenia or Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score ≤ -1.0.~12. Previous known allergy to the materials contained in the device, such as polyetheretherketone (PEEK) or titanium alloy (TAN);~13. Morbid obesity defined as a body mass index \> 40 kg/m2 or weight more than 100 pounds over ideal body weight;~14. Active malignancy. A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and there has been no clinical signs or symptoms of the malignancy for more than 5 years;~15. Current or recent history (within last 2 years) of substance abuse (e.g., recreational drugs, narcotics, or alcohol);~16. Pregnant or planning to become pregnant during study period;~17. Involved in study of another investigational product that may affect outcome;~18. History of psychosocial disorders that could prevent accurate completion of self reporting assessment scales;~19. Patients who are incarcerated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: OTHER): Treatment of cervical DDD with the Zero-P device

Based on this trial design, predict the completion outcome and termination type (if applicable).